… with anti-PD-L1 immunotherapy relieves T cell suppression and inhibits tumor growth.
Zoledronic acid (ZA) is a clinically available drug for bone metastases by targeting osteoclasts 35,…

… , support targeted therapy and immunotherapy. The combination of ablative therapy and …
immune checkpoints (programmed cell death protein-1 [PD-1] and PD-1 cognate ligand [PD-L1])…

… significance of programmed cell death protein-1 (PD-1)-targeted immunotherapy in Chinese
… Our findings suggest that (I) PD-1 targeted immunotherapy with toripalimab, camrelizumab, …

… Immunotherapy targeting the programmed cell death protein-1 (PD-1)/programmed cell death
protein ligand 1 (PD-L1) … tumor cells and CD8 + T cells were discovered in hepatocellular …

… In this review, the updated data from early-phase trials of combination immunotherapy for …
targeting the programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) …

… cells used for cellular immunotherapy. To test this possibility, we constructed the hepatitis
B virus (HBV) surface protein-specific chimeric antigen receptor T cells (HBVs-CAR-T cells) …

… Apoptosis is an active programmed cell death caused by … The apoptosis activation pathway
is diverse, including intrinsic … treatment of advanced cancers, such as renal and liver cancers (…

… , checkpoint blockade immunotherapy targeting programmed cell death protein 1 (PD-1)
has produced promising clinical efficacy in HCC patients. Nivolumab and pembrolizumab, two …

… TIGIT is a co-inhibitory receptor, and its suitability as a target for cancer immunotherapy in
HCC is unknown. PD1 blockade is clinically effective in about 20% of advanced HCC patients. …

… A number of innovative therapeutic approaches have been proposed, including some
fascinating combination strategies involving targeted therapies and immunotherapies that provide …